RHACE 1, NCT02098616: Rapid Hepatitis C Elimination Trial- A Pilot Study of Daclatasvir/Asunaprevir/BMS-791325 With or Without Ribavirin To Treat Hepatitis C Virus |
|
|
| Completed | N/A | 25 | US | DCV/ASV/BMS-791325, Fixed Dose Combination (FDC) of Daclatasvir/Asunaprevir/BMS-791325, DCV/ASV/BMS-791325 + RBV | Timothy Morgan, MD, VA Long Beach Healthcare System, National Cancer Institute (NCI), Bristol-Myers Squibb | Hepatitis C | 02/16 | 02/16 | | |